This finding is in line with the results found in a sub-analysis of the JAVELIN 101 trial, a phase 3 trial of advanced renal cell cancer patients treated with a combination of a tyrosine kinase inhibitor and an anti-PD-L1 antibody, in which the routine monitoring of cardiac biomarkers in asymptomatic patients was not useful for the early detection of CV irAEs [9]. Here, CD274 is linked to renal cell adenocarcinoma.